S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.21
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.51
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
DNTH · Dianthus Therapeutics, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Dianthus Therapeutics Inc (DNTH)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$78.14
-0.67
(-0.86%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$78.14
$77.52
$80.30
52-WEEK RANGE
$78.14
$32.22
$117.88
What's happening
- DNTH is down 0.86% today, trading at $78.14. — Live quote
- Volume today (38,491) is well below its 3-month average of 965,690. (Finnhub fundamentals)
- Reports earnings on 2026-11-05, 14 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-0.90 actual vs. $-0.87 estimated (-2.9%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 10
Buy 12
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (23 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
DNTH
+91.09%
vs S&P 500
+78.32%
1-YEAR RETURN
DNTH
+118.75%
vs S&P 500
+104.19%
6-MONTH RETURN
DNTH
-15.23%
3-MONTH RETURN
DNTH
-25.51%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.90
Est. $-0.87
MISS -2.9%
2026-04-26 (Q1 2026)
$-0.85
Est. $-1.09
BEAT +22.3%
2026-01-26 (Q4 2025)
$-1.43
Est. $-1.10
MISS -30.3%
2025-10-26 (Q3 2025)
$-0.97
Est. $-0.88
MISS -10.3%
Valuation Measures & Ratios
Enterprise Value4$4.24B
Forward P/E5—
PEG Ratio6-0.69
Price / Sales (TTM1)2285.70
Price / Book74.55
EV4 / Revenue2227.64
EV4 / EBITDA—
Profit Margin-10096.95%
Operating Margin-11441.39%
Return on Equity (ROE8)-22.53%
Return on Assets (ROA9)-21.55%
Avg Volume (3M)965,690
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $5.44B | $4.03B | $1.49B | $672.8M | $650.7M |
| P/E | -34.11 | -29.04 | -12.12 | -6.47 | -7.56 |
| Price/Sales | — | — | 380.28 | 124.81 | 107.16 |
| Price/Book | 4.64 | 3.35 | 2.73 | 2.22 | 1.98 |
| EV/Revenue | — | — | 366.01 | 122.35 | 105.49 |
| ROE | -13.60% | -11.55% | -22.52% | -34.29% | -26.18% |
| ROA | -13.14% | -11.13% | -21.31% | -31.87% | -24.68% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short9,140,581
Change from Prior Settlement+3.52%
% of Float—
Days to Cover (Short Ratio)8.32
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 294.3% on the provider's reported measure. Finnhub fundamentals ↗
- Trailing 52-week price return is +118.8%. Finnhub market metrics ↗
Potential concerns
- Net profit margin is -10097.0%. Finnhub fundamentals ↗
- Latest SEC filing is Form 4, filed 2026-09-18; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on DNTH
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $396.0K | $193.0K | $1.2M | $2.2M | $1.9M | $874.0K |
| Operating income | -$61.5M | -$46.5M | -$40.3M | -$34.9M | -$33.2M | -$29.9M | -$22.2M | -$17.8M |
| Net income | -$50.2M | -$40.8M | -$36.8M | -$31.6M | -$29.5M | -$25.2M | -$17.6M | -$13.7M |
| EPS (diluted) | $-0.90 | $-0.85 | $-0.97 | $-0.88 | $-0.82 | $-0.74 | $-0.51 | $-0.54 |
| EPS (basic) | $-0.90 | $-0.85 | $-0.97 | $-0.88 | $-0.82 | $-0.74 | $-0.51 | $-0.54 |
| Operating margin | — | — | -$10.2K | -$18.1K | -$2.9K | -$1.4K | -$1.2K | -$2.0K |
| Net margin | — | — | -$9.3K | -$16.4K | -$2.5K | -$1.2K | -$945 | -$1.6K |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $1.21B | $1.25B | $530.9M | $577.4M | $326.1M | $348.6M | $374.0M | $354.2M |
| Total liabilities | $41.2M | $45.6M | $37.5M | $31.0M | $23.0M | $20.0M | $21.5M | $16.4M |
| Stockholders' equity | $1.17B | $1.20B | $493.4M | $546.5M | $303.1M | $328.6M | $352.5M | $337.9M |
| Total current assets | $897.5M | $1.12B | $409.4M | $413.8M | $263.6M | $271.0M | $280.9M | $287.5M |
| Total current liabilities | $34.4M | $38.3M | $30.7M | $23.9M | $20.1M | $17.0M | $18.5M | $15.7M |
| Cash & equivalents | $110.5M | $627.7M | $51.1M | $56.0M | $13.2M | $10.1M | $22.8M | $33.7M |
| Marketable securities (current) | $776.3M | $483.6M | $353.2M | $346.6M | $244.2M | $253.1M | $252.4M | $247.5M |
| Accounts receivable | $106.0K | $1.2M | $52.0K | $5.0M | $39.0K | $1.0M | $0 | $1.4M |
| Other current assets | $184.0K | $83.0K | $86.0K | $73.0K | $111.0K | $392.0K | $355.0K | — |
| Marketable securities (non-current) | $303.6M | $113.9M | $110.1M | $152.9M | $51.7M | $68.3M | $81.7M | $61.5M |
| Property, plant & equipment | $418.0K | $274.0K | $296.0K | $185.0K | $207.0K | $191.0K | $194.0K | $189.0K |
| Other non-current assets | — | — | — | — | — | — | — | — |
| Accounts payable | $6.4M | $5.3M | $9.7M | $6.7M | $5.4M | $8.3M | $4.6M | $7.6M |
| Accrued liabilities | $26.1M | $31.1M | $19.5M | $16.0M | $14.0M | $8.0M | $13.1M | $7.7M |
| Deferred revenue (current) | $1.5M | $1.5M | $1.2M | $954.0K | $479.0K | $479.0K | $479.0K | $100.0K |
| Common stock & paid-in capital | $55.0K | $54.0K | $43.0K | $43.0K | $32.0K | $32.0K | $31.0K | $29.0K |
| Retained earnings | -$427.8M | -$377.6M | -$336.7M | -$272.3M | -$235.5M | -$203.9M | -$174.4M | -$146.0M |
| Accumulated other comprehensive income (loss) | -$2.1M | -$575.0K | $489.0K | $163.0K | $98.0K | $270.0K | $106.0K | $681.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$49.0M | -$28.9M | -$47.0M | -$30.6M | -$23.9M | -$27.6M | -$27.4M | -$21.3M |
| Investing cash flow | -$478.5M | -$134.0M | $37.2M | -$201.3M | $26.4M | $14.8M | -$23.1M | -$259.4M |
| Financing cash flow | $10.4M | $739.4M | $4.9M | $274.5M | $568.0K | $161.0K | $39.7M | $296.0K |
| Capital expenditures | — | — | — | — | — | — | — | — |
| Depreciation & amortization | — | — | — | — | — | — | — | — |
| Share-based compensation | $11.9M | $10.6M | $6.0M | $5.8M | $5.7M | $5.3M | $3.9M | $3.8M |
| Change in accounts receivable | -$1.1M | $1.2M | -$4.9M | $5.0M | -$961.0K | $1.0M | $0 | $0 |
| Change in accounts payable | — | — | — | — | — | — | — | — |
| Purchases of investments | $565.8M | $238.6M | $54.7M | $279.8M | $33.1M | $67.3M | $108.1M | $278.3M |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $2.0M | $6.2M | $2.8M | — | — |
| Operating income | -$177.9M | -$101.9M | -$48.2M | -$29.7M | -$74.7M |
| Net income | -$162.3M | -$85.0M | -$43.6M | -$28.5M | -$71.1M |
| EPS (diluted) | $-4.20 | $-2.55 | $-8.45 | $-32.57 | $-1.29 |
| EPS (basic) | $-4.20 | $-2.55 | $-8.45 | $-32.57 | $-1.29 |
| Operating margin | -$8.7K | -$1.6K | -$1.7K | — | — |
| Net margin | -$8.0K | -$1.4K | -$1.5K | — | — |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $530.9M | $374.0M | $179.4M | $83.1M | $189.9M |
| Total liabilities | $37.5M | $21.5M | $10.5M | $9.5M | $17.3M |
| Stockholders' equity | $493.4M | $352.5M | $168.9M | -$44.4M | -$17.2M |
| Total current assets | $409.4M | $280.9M | $177.5M | $82.0M | $180.7M |
| Total current liabilities | $30.7M | $18.5M | $9.6M | $8.2M | $10.9M |
| Cash & equivalents | $51.1M | $22.8M | $132.3M | $15.4M | $131.7M |
| Marketable securities (current) | $353.2M | $252.4M | $41.4M | $60.1M | — |
| Accounts receivable | $52.0K | $0 | $294.0K | $4.7M | — |
| Other current assets | $86.0K | $355.0K | $0 | — | — |
| Marketable securities (non-current) | $110.1M | $81.7M | $0 | — | — |
| Property, plant & equipment | $296.0K | $194.0K | $185.0K | $142.0K | $7.5M |
| Other non-current assets | — | — | — | — | — |
| Accounts payable | $9.7M | $4.6M | $2.6M | $1.2M | $3.0M |
| Accrued liabilities | $19.5M | $13.1M | $6.5M | $6.6M | $7.8M |
| Deferred revenue (current) | $1.2M | $479.0K | $0 | $100.0K | — |
| Common stock & paid-in capital | $43.0K | $31.0K | $15.0K | $0 | $59.0K |
| Retained earnings | -$336.7M | -$174.4M | -$89.4M | -$45.9M | -$325.6M |
| Accumulated other comprehensive income (loss) | $489.0K | $106.0K | $47.0K | -$161.0K | -$30.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$129.1M | -$78.2M | -$36.9M | -$29.1M | -$59.5M |
| Investing cash flow | -$122.8M | -$286.8M | $20.3M | -$59.8M | $43.4M |
| Financing cash flow | $280.1M | $255.6M | $133.6M | $96.7M | $89.6M |
| Free cash flow | — | — | — | -$29.4M | -$60.8M |
| Capital expenditures | — | — | — | $314.0K | $1.3M |
| Depreciation & amortization | — | — | — | $1.9M | $2.0M |
| Share-based compensation | $22.8M | $12.9M | $2.9M | $1.5M | $10.3M |
| Change in accounts receivable | $52.0K | $0 | — | — | — |
| Change in accounts payable | — | — | — | -$801.0K | -$720.0K |
| Purchases of investments | $435.0M | $413.7M | $57.4M | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding DNTH as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-03-12 to 2026-09-17
Recent transactions
- Insiders have net sold 330,807 shares over the last 182 days, across 0 purchases and 39 sales.
- Most recent: CARR EDWARD (CHIEF ACCOUNTING OFFICER) — Option exercise of 20,000 shares on 2026-09-17.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)330,807 sh(39 txns)
Net Shares-330,807
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| CARR EDWARD | CHIEF ACCOUNTING OFFICER | Option exercise | 2026-09-17 | 20,000 |
| Randhawa Simrat | EVP, Head of R&D | Option exercise | 2026-09-01 | 7,500 |
| Read Simon | Reporting person | Option exercise | 2026-08-19 | 2,778 |
| Veness Adam M | SVP, General Counsel and Sec. | Option exercise | 2026-08-13 | 15,000 |
| McGeorge Anne | Reporting person | Option exercise | 2026-08-10 | 1,250 |
| Garcia Marino | CEO AND PRESIDENT | Option exercise | 2026-08-07 | 40,000 |
| Savitz Ryan | EVP, CFO & CBO | Option exercise | 2026-07-09 | 31,249 |
| Soteropoulos Paula | Reporting person | Option exercise | 2026-05-08 | 599 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-17 | CARR EDWARD | CHIEF ACCOUNTING OFFICER | Option exercise | 20,000 | $17.88 |
| 2026-09-17 | CARR EDWARD | CHIEF ACCOUNTING OFFICER | Open market sale | 7,928 | $100.43 |
| 2026-09-17 | CARR EDWARD | CHIEF ACCOUNTING OFFICER | Open market sale | 6,771 | $101.37 |
| 2026-09-17 | CARR EDWARD | CHIEF ACCOUNTING OFFICER | Open market sale | 3,501 | $102.39 |
| 2026-09-17 | CARR EDWARD | CHIEF ACCOUNTING OFFICER | Open market sale | 1,100 | $103.20 |
| 2026-09-17 | CARR EDWARD | CHIEF ACCOUNTING OFFICER | Open market sale | 700 | $104.39 |
| 2026-09-01 | Randhawa Simrat | EVP, Head of R&D | Option exercise | 7,500 | $17.88 |
| 2026-09-01 | Randhawa Simrat | EVP, Head of R&D | Option exercise | 6,249 | $21.77 |
| 2026-09-01 | Randhawa Simrat | EVP, Head of R&D | Option exercise | 9,375 | $22.07 |
| 2026-09-01 | Randhawa Simrat | EVP, Head of R&D | Open market sale | 2,600 | $105.19 |
| 2026-09-01 | Randhawa Simrat | EVP, Head of R&D | Open market sale | 7,215 | $106.25 |
| 2026-09-01 | Randhawa Simrat | EVP, Head of R&D | Open market sale | 13,309 | $106.74 |
| 2026-08-19 | Read Simon | Reporting person | Option exercise | 2,778 | $18.36 |
| 2026-08-19 | Read Simon | Reporting person | Open market sale | 2,778 | $117.55 |
| 2026-08-13 | Veness Adam M | SVP, General Counsel and Sec. | Option exercise | 15,000 | $18.17 |
| 2026-08-10 | McGeorge Anne | Reporting person | Option exercise | 1,250 | $19.36 |
| 2026-08-10 | McGeorge Anne | Reporting person | Option exercise | 6,500 | $11.20 |
| 2026-08-10 | McGeorge Anne | Reporting person | Open market sale | 1,450 | $107.58 |
| 2026-08-10 | McGeorge Anne | Reporting person | Open market sale | 2,800 | $108.38 |
| 2026-08-10 | McGeorge Anne | Reporting person | Open market sale | 1,800 | $109.30 |
| 2026-08-10 | McGeorge Anne | Reporting person | Open market sale | 1,000 | $110.64 |
| 2026-08-10 | McGeorge Anne | Reporting person | Open market sale | 700 | $111.41 |
| 2026-08-10 | Read Simon | Reporting person | Option exercise | 2,777 | $18.36 |
| 2026-08-10 | Read Simon | Reporting person | Open market sale | 70 | $107.11 |
| 2026-08-10 | Read Simon | Reporting person | Open market sale | 737 | $108.17 |
| 2026-08-10 | Read Simon | Reporting person | Open market sale | 831 | $108.95 |
| 2026-08-10 | Read Simon | Reporting person | Open market sale | 272 | $109.96 |
| 2026-08-10 | Read Simon | Reporting person | Open market sale | 470 | $111.05 |
| 2026-08-10 | Read Simon | Reporting person | Open market sale | 397 | $111.77 |
| 2026-08-10 | Veness Adam M | SVP, General Counsel and Sec. | Option exercise | 16,167 | $17.88 |
| 2026-08-10 | Veness Adam M | SVP, General Counsel and Sec. | Open market sale | 16,167 | $110.38 |
| 2026-08-07 | Veness Adam M | SVP, General Counsel and Sec. | Option exercise | 3,833 | $17.88 |
| 2026-08-07 | Veness Adam M | SVP, General Counsel and Sec. | Open market sale | 3,217 | $110.61 |
| 2026-08-07 | Veness Adam M | SVP, General Counsel and Sec. | Open market sale | 616 | $111.18 |
| 2026-08-07 | Garcia Marino | CEO AND PRESIDENT | Option exercise | 40,000 | $8.44 |
| 2026-08-07 | Garcia Marino | CEO AND PRESIDENT | Option exercise | 126,000 | $8.44 |
| 2026-08-07 | Garcia Marino | CEO AND PRESIDENT | Open market sale | 10,384 | $107.49 |
| 2026-08-07 | Garcia Marino | CEO AND PRESIDENT | Open market sale | 23,907 | $108.05 |
| 2026-08-07 | Garcia Marino | CEO AND PRESIDENT | Open market sale | 2,373 | $109.10 |
| 2026-08-07 | Garcia Marino | CEO AND PRESIDENT | Open market sale | 2,536 | $110.02 |
| 2026-08-07 | Garcia Marino | CEO AND PRESIDENT | Open market sale | 800 | $110.76 |
| 2026-08-07 | Garcia Marino | CEO AND PRESIDENT | Open market sale | 104,091 | $107.96 |
| 2026-08-07 | Garcia Marino | CEO AND PRESIDENT | Open market sale | 21,909 | $108.72 |
| 2026-07-09 | Savitz Ryan | EVP, CFO & CBO | Option exercise | 31,249 | $21.77 |
| 2026-07-09 | Savitz Ryan | EVP, CFO & CBO | Open market sale | 10,354 | $100.22 |
| 2026-07-09 | Savitz Ryan | EVP, CFO & CBO | Open market sale | 15,329 | $101.24 |
| 2026-07-09 | Savitz Ryan | EVP, CFO & CBO | Open market sale | 5,566 | $101.97 |
| 2026-06-17 | Veness Adam M | SVP, General Counsel and Sec. | Option exercise | 30,000 | $17.88 |
| 2026-06-17 | Veness Adam M | SVP, General Counsel and Sec. | Open market sale | 16,771 | $80.34 |
| 2026-06-17 | Veness Adam M | SVP, General Counsel and Sec. | Open market sale | 13,229 | $81.38 |
| 2026-06-01 | Randhawa Simrat | EVP, Head of R&D | Option exercise | 3,998 | $8.44 |
| 2026-06-01 | Randhawa Simrat | EVP, Head of R&D | Option exercise | 6,908 | $17.88 |
| 2026-06-01 | Randhawa Simrat | EVP, Head of R&D | Option exercise | 6,249 | $21.77 |
| 2026-06-01 | Randhawa Simrat | EVP, Head of R&D | Option exercise | 9,375 | $22.07 |
| 2026-06-01 | Randhawa Simrat | EVP, Head of R&D | Open market sale | 5,428 | $89.72 |
| 2026-06-01 | Randhawa Simrat | EVP, Head of R&D | Open market sale | 16,943 | $90.72 |
| 2026-06-01 | Randhawa Simrat | EVP, Head of R&D | Open market sale | 4,159 | $91.37 |
| 2026-05-08 | Soteropoulos Paula | Reporting person | Option exercise | 599 | $8.44 |
| 2026-05-08 | Soteropoulos Paula | Reporting person | Open market sale | 599 | $85.47 |
| 2026-04-09 | Savitz Ryan | EVP, CFO & CBO | Option exercise | 8,224 | $17.88 |
Showing the most recent 60 transactions.
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 02:11 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-18 | 4 | 2026-09-17 | View on SEC.gov → |
| 2026-09-03 | 4 | 2026-09-01 | View on SEC.gov → |
| 2026-08-19 | 4 | 2026-08-19 | View on SEC.gov → |
| 2026-08-14 | 4 | 2026-08-13 | View on SEC.gov → |
| 2026-08-11 | 4 | 2026-08-10 | View on SEC.gov → |
| 2026-08-11 | 4 | 2026-08-10 | View on SEC.gov → |
| 2026-08-11 | 4 | 2026-08-07 | View on SEC.gov → |
| 2026-08-07 | 4 | 2026-08-07 | View on SEC.gov → |
| 2026-08-04 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-04 | 8-K | 2026-08-04 | View on SEC.gov → |
| 2026-07-13 | 4 | 2026-07-09 | View on SEC.gov → |
| 2026-06-18 | 4 | 2026-06-17 | View on SEC.gov → |
Recent news
Headlines about DNTH (Dianthus Therapeutics, Inc.). Links open the publisher — we don’t host full articles.
-
Dianthus Therapeutics (DNTH) Stock May Be Above Fair Value Following Its 5x Run
Yahoo · 2026-10-20 -
DNTH Mar 2027 50.000 put (DNTH270319P00050000) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-20 -
DNTH Dec 2027 100.000 call (DNTH271217C00100000) Interactive Stock Chart
Yahoo! Finance Canada · 2026-10-18 -
DNTH Dec 2027 100.000 call (DNTH271217C00100000) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-18 -
451,597 Dianthus Therapeutics, Inc. $DNTH Shares Purchased by Assenagon Asset Management S.A.
MarketBeat · 2026-10-17 -
(DNTH) Movement as an Input in Quant Signal Sets
Stock Traders Daily · 2026-10-16 -
DNTH Mar 2027 40.000 call (DNTH270319C00040000) Interactive Stock Chart - Yahoo Finance
Yahoo! Finance Canada · 2026-10-16 -
DNTH Feb 2027 75.000 put (DNTH270219P00075000) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-16
No headlines in this category right now — try “All”.